Benjamin Derman to Antibodies, Monoclonal
This is a "connection" page, showing publications Benjamin Derman has written about Antibodies, Monoclonal.
Connection Strength
1.341
-
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. Oncologist. 2024 09 06; 29(9):806-810.
Score: 0.542
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
Score: 0.532
-
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2025 Mar 03; 10(2):235-249.
Score: 0.140
-
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 10 10; 7(19):5703-5712.
Score: 0.127